- Home
- PK vs SLNO Comparison
PK vs SLNO Comparison
Compare PK & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PK
- SLNO
- Stock Information
- Founded
- PK 1946
- SLNO 1999
- Country
- PK United States
- SLNO United States
- Employees
- PK N/A
- SLNO N/A
- Industry
- PK Real Estate Investment Trusts
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- PK Real Estate
- SLNO Health Care
- Exchange
- PK Nasdaq
- SLNO Nasdaq
- Market Cap
- PK 2.5B
- SLNO 2.3B
- IPO Year
- PK N/A
- SLNO 2014
- Fundamental
- Price
- PK $10.91
- SLNO $71.99
- Analyst Decision
- PK Buy
- SLNO Strong Buy
- Analyst Count
- PK 11
- SLNO 8
- Target Price
- PK $17.95
- SLNO $92.00
- AVG Volume (30 Days)
- PK 4.7M
- SLNO 1.8M
- Earning Date
- PK 05-05-2025
- SLNO 05-08-2025
- Dividend Yield
- PK 12.83%
- SLNO N/A
- EPS Growth
- PK 129.54
- SLNO N/A
- EPS
- PK 1.01
- SLNO N/A
- Revenue
- PK $2,611,000,000.00
- SLNO N/A
- Revenue This Year
- PK $3.56
- SLNO N/A
- Revenue Next Year
- PK $3.55
- SLNO N/A
- P/E Ratio
- PK $10.81
- SLNO N/A
- Revenue Growth
- PK N/A
- SLNO N/A
- 52 Week Low
- PK $10.84
- SLNO $36.61
- 52 Week High
- PK $17.87
- SLNO $73.97
- Technical
- Relative Strength Index (RSI)
- PK 34.11
- SLNO 84.44
- Support Level
- PK $10.89
- SLNO $48.29
- Resistance Level
- PK $11.65
- SLNO $51.88
- Average True Range (ATR)
- PK 0.39
- SLNO 3.03
- MACD
- PK -0.00
- SLNO 2.32
- Stochastic Oscillator
- PK 4.89
- SLNO 93.61
About PK Park Hotels & Resorts Inc.
Park Hotels & Resorts owns upper-upscale and luxury hotels with 22,711 rooms across 37 hotels in the United States. Park also has interests through joint ventures in another 2,271 rooms in three US hotels. Park was spun out of narrow-moat Hilton Worldwide Holdings at the start of 2017, so most of the company's hotels are still under Hilton brands. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.